Search company, investor...

Critical Path Institute

c-path.org

Founded Year

2005

Stage

Grant - III | Alive

About Critical Path Institute

Critical Path Institute is an independent non-profit organization established as a public and private partnership. Its mission is to catalyze the development of new approaches that advance medical discoveries and regulatory science, accelerating the path to a healthier world. Critical Path Institute has established numerous global consortia that include scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. Critical Path Institute was founded in 2005 and is based in Tucson, Arizona.

Headquarters Location

1730 E. River Rd., #200

Tucson, Arizona, 85718,

United States

520 547-3440

Missing: Critical Path Institute's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Critical Path Institute's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Critical Path Institute News

FDA initiates the Lysosomal Diseases Pre-Consortium at the Critical Path Institute

Sep 2, 2022

02-09-2022 The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has announced its partnership with the  Critical Path Institute (C-Path)  to explore the feasibility of launching the Lysosomal Diseases Consortium, a public-private partnership among FDA, leading academic institutions, pharmaceutical industries, patient groups, and non-government organizations to address unmet drug development needs for patients… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Critical Path Institute Frequently Asked Questions (FAQ)

  • When was Critical Path Institute founded?

    Critical Path Institute was founded in 2005.

  • Where is Critical Path Institute's headquarters?

    Critical Path Institute's headquarters is located at 1730 E. River Rd., #200, Tucson.

  • What is Critical Path Institute's latest funding round?

    Critical Path Institute's latest funding round is Grant - III.

  • Who are the investors of Critical Path Institute?

    Investors of Critical Path Institute include U.S. Food and Drug Administration, Frederick Gardner Cottrell Foundation and Bill & Melinda Gates Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.